Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
3.4
Journals
JPM
Special Issues
Personalized Medicine in Spondyloarthritis
share announcement

Personalized Medicine in Spondyloarthritis

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: 15 September 2024 | Viewed by 1009

Special Issue Editor

Prof. Dr. Codrina Ancuta

E-Mail Website
Guest Editor
Rheumatology Department, University of Medicine and Pharmacy “Grigore T Popa”, 700115 Iasi, Romania
Interests: immune-mediated inflammatory rheumatic disorders; rheumatoid arthritis, spondyloarthritis; connective tissue diseases; systemic sclerosis, systemic lupus erythematosus, poli/dermatomyositis; biological therapies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Spondyloarthritis (SpA) represents a heterogeneous group of rheumatic inflammatory entities involving the axial skeleton, enthesis, and peripheral joints and may occur together with extra-articular manifestations, such as psoriasis, inflammatory bowel disease, and uveitis.

Important advances in the understanding of SpA have been made in the area of classification criteria, significantly improving the approach to these diseases and the identification of patients in early stages of the disease. Numerous studies have elucidated the immune mechanisms underlying specific clinical manifestations of the disease, opening the way to new and more personalized therapeutic approaches. In particular, new and more specific treatments promise to make feasible treat-to-target and drug-free remission in SpA, which were once impossible objectives. Although the diagnostic delay in SpA is still considerable, the increased awareness and insights into diagnosis at early stages of the disease are contributing to improving its management.

The present Special Issue aims to deepen the knowledge of SpA from bench to bedside, providing a broad update on the pathophysiological, diagnostic, and therapeutic aspects of the disease.

Prof. Dr. Codrina Ancuta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • spondyloarthritis
  • biologics
  • diagnostic biomarkers
  • therapeutic biomarkers
  • spondyliarthritis comorbidities
  • genetics of SpA
  • pathophysiology of SpA
  • established therapeutic approaches in SpA
  • new therapeutic approaches in SpA

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 1501 KiB  
Article
Long-Term Outcomes of Patients with Biologically Treated Psoriatic Arthritis and Atopic Dermatitis—A Single-Center Experience
by Georgiana Strugariu, Cristina Pomîrleanu, Mara Russu, Alexandra Popescu, Luiza Andreea Petrariu, Eugen Ancuta, Rodica Chirieac, Doinița Temelie-Olinici and Codrina Ancuța
J. Pers. Med. 2024, 14(4), 427; https://doi.org/10.3390/jpm14040427 - 17 Apr 2024
Viewed by 272
Abstract
(1) Background: Although the association between psoriasis and atopic dermatitis (AD) is reported in the literature, scarce data are known about the efficacy of biologic therapy (including TNF and IL-17 inhibitors) in patients with psoriatic arthritis (PsA) and concomitant AD. (2) Objective: We [...] Read more.
(1) Background: Although the association between psoriasis and atopic dermatitis (AD) is reported in the literature, scarce data are known about the efficacy of biologic therapy (including TNF and IL-17 inhibitors) in patients with psoriatic arthritis (PsA) and concomitant AD. (2) Objective: We aimed to explore AD in patients with PsA undergoing biologics for their active disease, focusing on prevalence and clinical and potential therapeutic implications. (3) Material and methods: We performed a retrospective analysis of 64 patients with PsA receiving various biological agents, followed-up in an academic outpatient rheumatology department up to 10 years. (4) Results: Atopic diseases were reported in about one third of cases, with a higher incidence of AD (10 cases; 52.6%) vs. atopic rhinitis (6 cases; 31.6%) and allergic asthma (3 cases; 15.8%). Three morphological patterns of AD were recognized including chronic prurigo (3 cases), a chronic lichen simplex (1 case), and eczemas (6 cases). All PsA with concomitant AD displayed a late onset of skin atopy (in their adult life) and demonstrated a specific profile (younger), from urban settings, equally distributed among genders, and requiring switching to a higher number of biologics to achieve disease control. (5) Conclusion: PsA and AD may coexist, requiring special attention when selecting the optimal biologic agent. Full article
(This article belongs to the Special Issue Personalized Medicine in Spondyloarthritis)
►▼ Show Figures

Figure 1

14 pages, 2357 KiB  
Article
Drug Survival, Effectiveness and Safety of Secukinumab in Axial Spondyloarthritis up to 4 Years: A Real-Life Single Center Experience
by Alexandra-Diana Diaconu, Cristina Pomîrleanu, Mara Russu, Georgiana Strugariu, Eugen Ancuța, Irina Ciortescu, Cristina Bologa, Bianca Codrina Morărașu, Mihai Constantin, Alexandr Ceasovschih, Victorița Șorodoc, Laurențiu Șorodoc and Codrina Ancuța
J. Pers. Med. 2024, 14(4), 417; https://doi.org/10.3390/jpm14040417 - 15 Apr 2024
Viewed by 331
Abstract
(1) Objective: The main aims of our study were to explore the drug survival and effectiveness of secukinumab in patients with axial spondyloarthritis (axSpA). (2) Methods: We underwent a retrospective analysis of consecutive axSpA treated with secukinumab as a first line of biologics [...] Read more.
(1) Objective: The main aims of our study were to explore the drug survival and effectiveness of secukinumab in patients with axial spondyloarthritis (axSpA). (2) Methods: We underwent a retrospective analysis of consecutive axSpA treated with secukinumab as a first line of biologics or at switch in a biologic-experienced population. Efficacy data, indicating improvement in inflammation parameters (such as C-reactive protein and erythrocyte sedimentation rate) and disease activity scores (such as Ankylosing Spondylitis Disease Activity Score [ASDAS-CRP], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI]), and patient-reported outcomes (pain), were assessed at 6, 12, 24, 36 and 48 months. The drug survival rate, dropout rate and discontinuation reasons (efficacy versus safety) of secukinumab were assessed in subgroup analysis (axSpA with and without exposure to biologics). (3) Results: In total, 46 patients were exposed to the IL-17A inhibitor secukinumab. The drug survival for axSpA patients 59.7% at 12 months and 31.3% at 24 months. There were no statistically significant differences in the median drug survival between biologic-naïve versus biologic-experienced subgroups. (4) Conclusions: Secukinumab has demonstrated effectiveness and safety in treating a cohort of axSpA patients in real-world settings, with a notable retention rate of the drug. Full article
(This article belongs to the Special Issue Personalized Medicine in Spondyloarthritis)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop